Početna › Limfom plaštanih stanica › Kalifornija
Kliničke studije za Limfom plaštanih stanica u državi Kalifornija
29 studija za Limfom plaštanih stanica traži sudionike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
- Baldwin Park15 studija
- Mountain View7 studija
- Los Angeles7 studija
- San Diego5 studija
- San Francisco4 studija
- Irvine3 studija
Službeni tekst studije (engleski)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
U tijeku regrutacijaFaza 3
Od 60 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT05976763Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- University of California, Davis, Davis
- University of California, Los Angeles, Los Angeles
- University of California, San Diego, San Diego
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Stanford Cancer Center, Stanford
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT06553872A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- City of Hope Comprehensive Cancer Center, Duarte
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT07003295A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 do 85 godina · Oba spola · Ažurirano 10. kol 2026. · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. srp 2026. · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 24. srp 2026. · NCT07121946DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. lip 2026. · NCT04545762Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- City of Hope Medical center, Duarte
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT03523975Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. tra 2026. · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- i još 1
U tijeku regrutacijaFaza 1/2
Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT06572618Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. velj 2026. · NCT05432635Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 5. sij 2026. · NCT06054776AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. stu 2025. · NCT05370430SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- i još 3
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Stanford Cancer Center, Palo Alto
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 22. kol 2024. · NCT05255354Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.